233 related articles for article (PubMed ID: 24151324)
21. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
[TBL] [Abstract][Full Text] [Related]
22. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
23. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
Lai Y
Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
[TBL] [Abstract][Full Text] [Related]
24. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
25. Suppression of Active HIV-1 Infection in CD34
Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
[TBL] [Abstract][Full Text] [Related]
26. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
27. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
[TBL] [Abstract][Full Text] [Related]
28. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.
Walker JE; Chen RX; McGee J; Nacey C; Pollard RB; Abedi M; Bauer G; Nolta JA; Anderson JS
J Virol; 2012 May; 86(10):5719-29. PubMed ID: 22398281
[TBL] [Abstract][Full Text] [Related]
29. Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV.
AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22023317
[No Abstract] [Full Text] [Related]
30. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.
Perez EE; Wang J; Miller JC; Jouvenot Y; Kim KA; Liu O; Wang N; Lee G; Bartsevich VV; Lee YL; Guschin DY; Rupniewski I; Waite AJ; Carpenito C; Carroll RG; Orange JS; Urnov FD; Rebar EJ; Ando D; Gregory PD; Riley JL; Holmes MC; June CH
Nat Biotechnol; 2008 Jul; 26(7):808-16. PubMed ID: 18587387
[TBL] [Abstract][Full Text] [Related]
31. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells.
DiGiusto DL; Cannon PM; Holmes MC; Li L; Rao A; Wang J; Lee G; Gregory PD; Kim KA; Hayward SB; Meyer K; Exline C; Lopez E; Henley J; Gonzalez N; Bedell V; Stan R; Zaia JA
Mol Ther Methods Clin Dev; 2016; 3():16067. PubMed ID: 27900346
[TBL] [Abstract][Full Text] [Related]
32. Efficient ZFN-Mediated Stop Codon Integration into the CCR5 Locus in Hematopoietic Stem Cells: A Possible Source for Intrabone Marrow Cell Transplantation.
Chattong S; Chaikomon K; Chaiya T; Tangkosakul T; Palavutitotai N; Anusornvongchai T; Manotham K
AIDS Res Hum Retroviruses; 2018 Jul; 34(7):575-579. PubMed ID: 29575905
[TBL] [Abstract][Full Text] [Related]
33. Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease.
Hu J; Feng Y; Ma P; Lai Y
Curr Stem Cell Res Ther; 2019; 14(7):591-597. PubMed ID: 31120000
[TBL] [Abstract][Full Text] [Related]
34. Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells.
Yao Y; Nashun B; Zhou T; Qin L; Qin L; Zhao S; Xu J; Esteban MA; Chen X
Hum Gene Ther; 2012 Feb; 23(2):238-42. PubMed ID: 21981760
[TBL] [Abstract][Full Text] [Related]
35. In vivo selection of anti-HIV-1 gene-modified human hematopoietic stem/progenitor cells to enhance engraftment and HIV-1 inhibition.
Guo Q; Zhang J; Parikh K; Brinkley A; Lin S; Zakarian C; Pernet O; Shimizu S; Khamaikawin W; Hacke K; Kasahara N; An DS
Mol Ther; 2024 Feb; 32(2):384-394. PubMed ID: 38087779
[TBL] [Abstract][Full Text] [Related]
36. Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.
Schleifman EB; Bindra R; Leif J; del Campo J; Rogers FA; Uchil P; Kutsch O; Shultz LD; Kumar P; Greiner DL; Glazer PM
Chem Biol; 2011 Sep; 18(9):1189-98. PubMed ID: 21944757
[TBL] [Abstract][Full Text] [Related]
37. The use of cell-delivered gene therapy for the treatment of HIV/AIDS.
Symonds GP; Johnstone HA; Millington ML; Boyd MP; Burke BP; Breton LR
Immunol Res; 2010 Dec; 48(1-3):84-98. PubMed ID: 20737298
[TBL] [Abstract][Full Text] [Related]
38. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
Bai J; Banda N; Lee NS; Rossi J; Akkina R
Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype.
Binninger-Schinzel D; Müller D; Wolf T; Krause B; Meye B; Winskowsky G; Raupp S; Norley S; Brodt R; Werner A
J Med Virol; 2008 Feb; 80(2):192-200. PubMed ID: 18098144
[TBL] [Abstract][Full Text] [Related]
40. Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice.
Picchio GR; Gulizia RJ; Mosier DE
J Virol; 1997 Sep; 71(9):7124-7. PubMed ID: 9261448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
